de la Hoz-Martín María P, González-Fernández Juan, Andreu-Ballester Juan Carlos, Hoivik Marte L, Ricanek Petr, Bruland Torunn, Sandvik Arne K, Cuéllar Carmen, Catalán-Serra Ignacio
Unidad de Parasitología, Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Fundación FISABIO-Salud Pública de Valencia, 46020 Valencia, Spain.
Pathogens. 2025 Aug 4;14(8):769. doi: 10.3390/pathogens14080769.
This study assessed the seroprevalence of anti- antibodies in Norwegian patients with inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and Crohn's disease (CD), compared with healthy controls. Associations between anti- antibody positivity and clinical or laboratory parameters in IBD were also explored. A total of 86 UC patients, 68 CD patients, and 41 healthy controls were prospectively enrolled from four Norwegian hospitals (2013-2022). Diagnosis and disease activity were established using standard clinical, endoscopic, and biomarker criteria. Serum samples were analyzed for total Ig, IgG, IgM, IgA, and IgE antibodies against and using ELISA. Anti- IgG seroprevalence was 4.9% in controls and 3.2% in IBD (3.5% UC, 2.9% CD). IgM seroprevalence was 0% in all groups. IgA seroprevalence was higher in IBD (16.2%) than controls (4.9%), with 14.0% in UC and 19.1% in CD. IgE seroprevalence was low across all groups. Smoking correlated with lower antibody levels and higher surgery rates. In UC, higher anti- IgG and IgE levels were associated with milder disease and better prognosis. Anti-TNFα and azathioprine treatments were linked to higher anti- IgA. Norwegian UC and CD patients had significantly higher anti- total Ig and IgA seroprevalence than healthy controls, indicating increased exposure or immune response. Anti- IgG and IgE may serve as markers of clinical activity in UC. Further research is warranted to clarify the clinical significance of these findings.
本研究评估了挪威炎症性肠病（IBD）患者，特别是溃疡性结肠炎（UC）和克罗恩病（CD）患者中抗抗体的血清流行率，并与健康对照进行比较。还探讨了IBD患者中抗抗体阳性与临床或实验室参数之间的关联。从挪威四家医院（2013 - 2022年）前瞻性招募了86例UC患者、68例CD患者和41名健康对照。使用标准临床、内镜和生物标志物标准确定诊断和疾病活动度。采用酶联免疫吸附测定（ELISA）分析血清样本中针对和的总免疫球蛋白（Ig）、IgG、IgM、IgA和IgE抗体。抗IgG血清流行率在对照组中为4.9%，在IBD患者中为3.2%（UC为3.5%，CD为2.9%）。IgM血清流行率在所有组中均为0%。IBD患者中IgA血清流行率（16.2%）高于对照组（4.9%），UC中为14.0%，CD中为19.1%。所有组中IgE血清流行率均较低。吸烟与较低的抗体水平和较高的手术率相关。在UC中，较高的抗IgG和IgE水平与病情较轻和预后较好相关。抗肿瘤坏死因子α（TNFα）和硫唑嘌呤治疗与较高的抗IgA相关。挪威UC和CD患者的抗总Ig和IgA血清流行率显著高于健康对照，表明暴露增加或免疫反应增强。抗IgG和IgE可能作为UC临床活动的标志物。有必要进一步研究以阐明这些发现的临床意义。
